Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

FibroFix™ Cartilage, silk-based implant for cartilage repair and regeneration, introducing a new paradigm in osteoarthritis treatment.

Descripción del proyecto

Nuevo implante regenerativo para prevenir el reemplazo total de rodilla

El deterioro o las lesiones del cartílago de la rodilla suelen provocar artrosis. Esta enfermedad crónica relacionada con dolor, rigidez y discapacidad grave disminuye la calidad de vida y representa una gran carga económica para los sistemas sanitarios. Sin embargo, los tratamientos existentes, como el reemplazo total de la articulación de la rodilla, son costosos y, a menudo, presentan complicaciones. El proyecto FibroFix Cartilage, financiado con fondos europeos, propone un implante ortopédico regenerativo que aborda el problema de las lesiones graves o artríticas del cartílago articular en la rodilla. El implante de seda es bioestable y biocompatible, emula la función del cartílago y favorece su regeneración a un coste significativamente menor que otras soluciones. El producto permite un uso prolongado de la articulación, aumenta la movilidad, reduce el dolor y retrasa o previene el reemplazo total de la rodilla.

Objetivo

FibroFix™ Cartilage, silk-based implant for cartilage repair and regeneration, introducing a new paradigm in osteoarthritis treatment.

Cartilage deterioration and injuries often lead to osteoarthritis (OA) – a long-term chronic disease resulting in bones rubbing together and creating pain, stiffness and severe disability. Knee cartilage injuries are very common and almost half of them go on to develop OA, which is second only to heart disease as a cause of work disability. Resulting from decreased quality
of life, hospitalizations and loss of productivity, the economic cost of OA is particularly high in every country that it has been estimated. Currently, all treatments available, including Total Knee joint Replacement (TKR) as the ultimate recourse, are inefficient and expensive: they involve pain, lengthy rehabilitation, frequent complications and high costs. Therefore, given
the increasing prevalence of knee OA, its associated burdens and the drawbacks of all available treatments, it is becoming increasingly important to develop an innovative cost-effective solution to this major public health problem worldwide.

FibroFix™ Cartilage is a well characterised, regenerative orthopaedic repair product to address the unmet and pressing clinical need of large and/or osteoarthritic articular cartilage lesions in the knee, developed by Orthox. It is biostable, biocompatible, emulates cartilage function and supports cartilage regeneration at the minimum cost effectiveness ratio. It allows resurfacing of large and/or potentially OA cartilage lesions, prolonged use of the joint, increased mobility, reduced pain and postponement or prevention of TKR. Smooth, robust, resilient, durable and lubricious, it is a unique combination to be applied in orthopaedics and biomaterials shifting the paradigm in knee OA treatment and up to 10 times less expensive than other solutions.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

SME-2 - SME instrument phase 2

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-EIC-SMEInst-2018-2020

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

ORTHOX LIMITED
Aportación neta de la UEn
€ 2 496 960,38
Dirección
66 INNOVATION DRIVE MILTON PARK
OX14 4RQ Abingdon
Reino Unido
Pyme
Sí
Región
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 3 567 086,25